Finance

Lists
VOR:NASDAQ
Vor Biopharma Inc
$23.03
-1.12%
(-0.26) 1D
$23.03
0.00% (0.00)
After hours
Closed: Aug 14, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for VOR...
Open
$23.33
High
$23.35
Low
$22.38
Mkt. cap
1.36B
Avg. vol.
1.11M
Volume
417.56K
52-wk high
$50.20
52-wk low
$6.50
EPS
-$43.00
Beta
1.73
Shares outstanding
59.16M
No. of employees
76
Open
$23.33
High
$23.35
Low
$22.38
Mkt. cap
1.36B
Avg. vol.
1.11M
Volume
417.56K
52-wk high
$50.20
52-wk low
$6.50
EPS
-$43.00
Beta
1.73
Shares outstanding
59.16M
No. of employees
76
News stories
From web sources and news partners
About Vor Biopharma Inc
CEO-
Employees76
Founded2015
HeadquartersBoston, Massachusetts, United States
SectorBiotechnology
Websitevorbio.com
Analyst ratings
Based on 4 analysts giving stock ratings to VOR in the past 3 months
Strong buy
Buy
3
Hold
1
Sell
0
12-month forecast
Based on 4 Wall Street analysts offering 12 month price targets for VOR in the last 3 months.
Highest
Current $23.03
$50.00 (+117.11%)
Average
$34.50 (+49.80%)
Lowest
$27.00 (+17.24%)
Analyst
Recommendation
Action
Price target
Projected
Date
Geoff Meacham
Citi
Buy
Maintained
$50.00
+117.1%
08/13/2026
Martin Fan
Wedbush
Hold
Maintained
$27.00
+17.2%
08/12/2026
Sadia Rahman
Wells Fargo
Buy
Reiterated
$30.00
+30.3%
08/12/2026
Swayampakula Ramakanth
H.C. Wainwright
Buy
Reiterated
$31.00
+34.6%
08/12/2026
Yaron Werber
TD Cowen
Buy
Maintained
-
-
05/13/2026
Stephen Willey
Stifel Nicolaus
Buy
Maintained
$40.00
+73.7%
04/08/2026
Farzin Haque
Jefferies
Buy
Initiated
$50.00
+117.1%
03/29/2026
Last report
Aug 11, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
-$1.16 / -$0.70
-65.01%miss
Revenue / Est. (USD)
- / 0.00
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
14.72M
19.19M
17.60M
25.92M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
14.42M
16.77M
17.56M
21.93M
Operating expense
29.14M
35.96M
35.16M
47.85M
Total operating expenses
29.14M
35.96M
35.16M
47.85M
Operating income
-29.14M
-35.96M
-35.16M
-47.85M
Other non operating income
-786.31M
1.75B
-188.36M
-19.30M
EBT including unusual items
-812.68M
1.72B
-219.58M
-62.81M
EBT excluding unusual items
-813.71M
1.72B
-219.58M
-62.81M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-812.68M
1.72B
-219.58M
-62.81M
Net profit margin
-
-
-
-
Earnings per share
-121.63
307.53
-0.73
-0.80
Interest and investment income
1.73M
2.80M
3.94M
4.34M
Interest expense
-
-
-
-
Net interest expenses
1.73M
2.80M
3.94M
4.34M
Depreciation and amortization charges
-
-
-
-
EBITDA
-29.13M
-35.94M
-35.13M
-47.82M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a portfolio
Create a task
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps